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We have previously shown that human interferon α-2b (IFN) produced in Escherichia coli (E. coli) 
is heterogeneous at the N-terminal, with three major species [1]. These are: (a) the direct translation 
product of the gene retaining the N-terminal methionine, (b) a species from which the methionyl 
residue has been removed by E. coli methionyl aminopeptidase to give the native interferon α-2b 
and (c) in which the N-terminal Cys residue of the latter contains an acetyl group. In this paper we 
overcome this heterogeneity, using engineered interferon derivatives with phenylalanine residue 
directly downstream of the N-terminal methionine (Met-Phe-IFN).  This modification not only 
prevented the removal of the N-terminal methionine by E. coli methionyl aminopeptidase but also 
the subsequent N-acetylation. Critically, Met-Phe-IFN had enhanced activity in a biological assay. 
N-terminal stabilization was also achieved by fusing human cytochrome b5 at the N-terminal of 
interferon (b5-IFN-chimera).  In this case also, the protein was more active than a reciprocal 
chimera with cytochrome b5 at the C-terminal of interferon (Met-IFN-b5-chimera).  This latter 
protein also had a heterogeneous N-terminal but addition of phenylalanine following Met, (Met-
Phe-IFN- b5-chimera), resolved this problem and gave enhanced biological activity.  
1. Introduction 
Following the original discovery in the late 1950s [2], in recent years, interferon (IFN, 1a Figure 
1) has gained recognition as a drug of choice for the treatment of many viral diseases and certain 
cancers [3].  Effective use of peptide and protein drugs in patients suffers from their instability in 
vivo, arising from rapid clearance rates, premature uptake by tissues (for instance the 
reticuloendothelial system), loss through the kidneys, and immunogenicity or antigenicity [4]. In 
order to prolong the plasma half-life of interferon a number of strategies have been employed, with 
the aim of increasing in vivo efficacy as well as reducing injection frequency hence helping to 
improve patients’ life quality.  Until now, conjugation of interferon with polyethylene glycol 
(PEG) has been the most successful approach. This, significantly reduces plasma interferon 
clearance and immunogenicity [4].   
In general, pegylation occurs randomly on the ε-amino group of surface lysine residues [4], though, 
site-specific pegylation has also been reported [5, 6].  For more specific targeting, however, fusion 
technology to graft a protein specifically to the N- or C-terminal of a drug has been developed.  
Albumin fusion to interferon is one such example [6, 7]. Most commonly, E. coli is the host of 
choice for the heterologous expression of recombinant proteins.  Expression of eukaryotic proteins 
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in a prokaryotic host such as E. coli leads, sometimes, to inclusion body formation requiring 
subsequent protein refolding.  The presence of disulfide bridges in proteins makes their refolding 
a complex and delicate task, not tractable for multi-thiol-containing fusion partners such as 
albumin, which have been produced in yeast [7, 8].    
Our previous work has shown that the expression of the Met-IFN encoding-DNA in E. coli leads 
to the production of a heterogeneous mixture of three products.  These are: (a) the direct translation 
product of the DNA retaining the N-terminal methionine (2 Figure 1), (b) a species from which 
the methionyl residue has been removed by E. coli methionyl aminopeptidase to give the native 
interferon α-2b (1a, Figure 1) and (c) a species in which the N-terminal Cys residue of the latter 
contains an acetyl group (1b, Figure 1).  In the present study two related problems have been 
addressed.  We firstly avoid the aforementioned processing of the N-terminal of interferon α-2b, 
by introducing a Phe residue following the initiator N-terminal Met of interferon α-2b (3 Figure 
1). Secondly, we constructed chimeras between interferon α-2b and human cytochrome b5 (4-6 
Figure 1).  Critically, cytochrome b5 contains no cysteine residues and thus the two disulfide 
bridges in the final product will be formed by the four cysteines of interferon α 2b.  We tested 
fusions of cytochrome b5 at the carboxy- or amino- terminal of interferon α-2b. Construct 4, 
(Figure 1) also had a counterpart containing a Phe residue penultimate to the N-terminal 
methionine.  The biological activities of these constructs were determined functionally using a 
novel method, involving sensitivity of lentiviral vector infection to the recombinant interferon 





 Figure 1. Interferon derivatives.  Interferon core, referring to interferon α-2b, is shown in blue, its N- 
and C-termini are emboldened and additions to N-terminal are shown by (-) numbers.  Cytochrome b5 
skeleton in the chimera is in red with the connecting residues (L-E) in black. 
 
2.  Results and Discussion 
2.1 The N-terminal heterogeneity  
Our previous study considering human Met-IFN engineering (structure 2 Figure 1) using E. coli, 
as a host, showed that the expressed protein consisted of three species: (a), IFN with an intact 
methionine (Met-IFN (2)), encoded by the DNA sequence, (b), IFN without its N terminal 
methionine (1a) formed by the action of host methionine aminopeptidase on the primary 
translation product of the gene (2) and (c), N-acetyl-IFN (1b) formed by the action of  E. coli 
acetyl transferase on IFN (1a) itself. 
We set out to prevent N-terminal heterogeneity taking several approaches. Unsuccessful 
approaches included engineering expression vectors that encoded Met-IFN, and methionine 
 5 
aminopeptidase aiming to convert the primary translation product into native IFN [9].  However, 
soon it became evident that the main cause of heterogeneity was the action of an acetyl transferase 
which, as we will see later, efficiently modified the IFN N-terminal amino group of Cys1.  
Notwithstanding, this heterogeneity, through careful HPLC separation we were able to obtain 
homogeneous native IFN. Commercial preparations of recombinant IFN, obtained from 
expression in E. coli are deemed to be homogenous, however, it is not known whether this is also 
the result of purification by HPLC or use of another genetic tool where terminal N-acetylation is 
avoided. In a novel PEGylation of interferon α-2b at one of the disulphide bonds, the MALDI 
spectrum in the paper, of the precursor interferon α-2b, was shown to have a mass of 19,306 Da  
[5] which corresponds to N-acetyl-interferon α-2b (2, Figure 1) and not interferon α-2b itself that 
would have a mass of 19,265 Da. The interferon used in the latter work was reported to be obtained 
from a yeast expression system. The specificities of yeast N-acetyl transferases have been studied, 
using a panel of proteins but in no case Cys modification was observed [10].  It would thus appear 
that a specific, but unknown, signal in interferon α-2b is recognized for acetylation by an acetyl 
transferase in yeast as well as E. coli.  
2.2 Expression of the gene for Met-Phe-IFN (3): analysis of the protein and of its tryptic peptides 
In order to avoid the heterogeneity, our subsequent efforts were aimed to use of an N-terminal 
sequence that was not susceptible to the action of methionine aminopeptidase.  Here, we took 
advantage of our studies on the preparation of a variety of proinsulin derivatives.  In general, these 
derivatives have a phenylalanine following the N-terminal methionine, that is, a Met-Phe sequence 
[11, 12]. In these derivatives we did not observe the removal of methionine or any other 
modification involving this residue. 
In the light of these observations, interferon derivative containing Met-Phe was engineered, 
expressed in E. coli and the inclusion bodies solubilized at pH 11.00. We serendipitously 
discovered that use of pH 11 greatly improved the yield of the correctly folded protein compared 
to pH 8.0, used in our previous study [1].  Unlike the HPLC profile of the refolded Met-IFN 
(Figure 2A.  Inset), Met-Phe-IFN (3) gave a single peak (Figure 2A) showing the desired Mr of 
19543.7 (19544.4, theoretical) on MALDI analysis (Figure 2B).  The purity of Met-Phe-IFN (3) 
was such that after the Q-sepharose step the mass spectral profile of the protein was 
indistinguishable from that of the HPLC peak (Figure 2B &C). [Figure 2 near here] 
 6 
 
Figure 2. (A) HPLC chromatogram of Met-Phe-IFN (3 Figure 1) eluting with 59-61% acetonitrile. . 
Inset shows the equivalent profile from the expression of the Met-IFN gene containing three species, IFN, 
N-acetyl-IFN and Met-IFN (peaks 1.2 and 3 respectively). (B and C) MALDI-TOF spectrum of Met-
Phe-IFN (3 Figure 1).  (B) Before and (C) after HPLC, showing the [M+H]+ ion (Cal. 19544.4).  
 
Tryptic digestion of Met-Phe-IFN, without prior cleavage of the disulphide bonds, followed by 
ESI-MS analysis, showed the presence of 92% of the theoretically possible peptides including 
those containing the correct disulphide bonds (Table S4 and structures I & II Figure S3a), in 
particular I which had the expected N-terminal sequence.  The folding process was thus unaffected 
by the N-terminal modification in Met-Phe-IFN.   
 
2.3 Expression of the genes for the chimeras 4, 5 and 6 (Figure 1): analysis of the proteins and of 
their tryptic peptides 
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Encouraged by the results on Met-Phe-IFN, we extended the use of this approach to fusion 
proteins involving interferon α-2b and cytochrome b5.  The most well used partner for bioactive 
peptide drugs is human serum albumin. The choice of this protein has been justified for a variety 
of reasons [13, 14] and its use is exemplified by human serum albumin-interferon fusion proteins 
[6, 7, 15-17], which are typically expressed in yeast [15]. The expression of such proteins in E. 
coli is problematic since serum albumin contains 35 cysteine residues engaged in 17 disulphide 
bonds.  Since the putative conjugate of the protein with interferon will add four further cysteine 
residues, the possibility of the formation of native disulphide bonds within each partner will be 
greatly reduced.  In order to avoid this complication we selected human cytochrome b5 as a fusion 
partner for interferon since it does not possess cysteine residues. 
Three fusion proteins were designed. Two of these contained the native interferon α-2b sequence 
ligated either to the N-or the C-terminal of cytochrome b5 (4 and 6 respectively, Figure 1).  In the 
third derivative, the sequence Met-Phe-IFN was placed at the cytochrome b5 N-terminal (5 Figure 
1). 
These fusion proteins were expressed in E. coli as inclusion bodies, which were solubilized and 
refolded as described for Met-Phe-IFN (3 Figure 1).  HPLC analysis of Met-IFN-b5-chimera (5 
Figure 1) showed the presence of three peaks. From their masses these were characterized as: (a) 
the translation product of the encoding-DNA retaining the N-terminal methionine (peak 3, Figure 
3), (b) where methionine had been removed (peak 1, Figure 3) and (c) in which the amino group 
of Cys residue had been acetylated (peak 2, Figure 3).  The profile with Met-IFN-b5-chimera (5 
Figure 1) is, thus, identical to that obtained from the expression of Met-IFN. [Figure 3 near here] 
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Figure 3.  HPLC chromatogram of the products from the expression of the Met-IFN-b5-chimera. 
Chromatogram containing three products is shown above.   Masses as determined by ESI are above the 
peaks 
 
The HPLC analysis of b5-IFN-chimera (4 Figure 1) again showed heterogeneity, giving three 
peaks (Figure 4A).  These corresponded to the primary translation product, loss of methionine, by 
the action of methionine aminopeptidase and further removal of the newly generated Ala by an 
unknown E. coli peptidase (Figure 4B-D). We have previously observed similar processing of the 
N-terminal residues of proteins, when the N-terminal methionine is followed by a small residue. 
Unlike, the preceding two chimeras (3 and 6 Figure 1) the fusion protein, Met-Phe-IFN-b5-
chimera (5 Figure 1) showed a single peak on HPLC, giving the expected mass Figure 5). [Figure 




Figure 4. RP-HPLC chromatogram and mass spectra of b5-IFN-chimera (6, Figure 1).  A, Protein was 
eluted in four chromatographic peaks (peak 0, 1, 2 & 3). B, C and D, MALDI-TOF spectra of the three 





Figure 5. (A), RP-HPLC profile of Met-Phe-IFN-b5-chimera (5, Figure 1) eluted at 50-61% 
acetonitrile. Inset shows the equivalent profile from the expression of the Met-IFN-b5-chimera containing 
three species, (B) ESI-MS of the protein before HPLC showing its Mr (cal. 31036.1); (C) ESI-MS of the 
protein after HPLC showing its Mr (cal. 31036.1). 
The correct disulphide bond formation by the three fusion proteins, 4, 5 and 6 (Figure 1) was 
established by mass spectrometric analysis of tryptic digests.  In the cases of the derivatives 4 and 
5 (Figure 1), the expected disulphide-bonded fragments (IIIa/ IIIb) plus (II, Figure 3Sb, 
Supplementary section 6) and (I) plus (II, Figure S3c, section 6) respectively were obtained 
showing that in each case the two disulphide bonds were between Cys1-Cys98 and Cys29-Cys138. 
With b5-IFN-chimera (6 Figure 1), the tryptic digest contained besides the Cys29-Cys138 fragment 
(II), the second disulphide-bond-fragment (IV, Figure S3d, section 6), which as expected, had 
sequences from the C-terminal of b5 as well as N-terminal of IFN. Thus, using the oxidative-
refolding conditions used in this work, the interferon motif underwent correct refolding, tolerating 
the extensions on either end of the molecule.    
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[Figure 6 near here]  
 
 
Figure 6: Reductive SDS-PAGE analysis of various interferon constructs after Q-sepharose 
column purification. Lanes: M; home-made ladder showing 66, 45, 30, 16 and 14 kDa species, 
A; Met-IFN, 2 (19.0 kDa), B; Met-Phe-IFN, 3 (19.5 kDa), C; Met-IFN-b5-chimera, 4 (30.8 kDa), 
D; Met-Phe-IFN-b5-chimera, 5 (31.0 kDa), E; b5-IFN-chimera, 6 (30.7 kDa). 
2.4 Antiviral activities of the various derivatives of interferon  
The SDS-PAGE profiles of all the five interferon derivatives (2-6 Figure 1) are shown in Figure 
6. With the availability of 4 new derivatives (3-6) their antiviral activities were assayed using 
pseudotyped viral particles expressing enhanced green fluorescent protein (eGFP) in the THP-1 
cell line [18].  This assay is based on the infection of target cells by  VSV-G pseudotyped HIV-1 
vector, carrying vesicular stomatitis virus G glycoprotein (VSV-G) in the envelop and eGFP as 
reporter gene. . The number of eGFP expressing cells was used as a measure of viral infection.  
Cells were pre-incubated with interferon or its derivatives and anti-viral activity was determined 
by the test molecules’ ability to reduce viral infection in the target cells A comparison of IC50values 
and relative bioactivities (%), calculated on a molar basis, is given in Table 1 which shows that 
Met-IFN (2, Table 1 and Figure 7) prepared in the present work had the same activity as a 
reference standard  In the light of the profile in Figure 7, the same five concentrations (0.0374, 
0.374, 3.74, 37.4 and 374 pM) which gave a satisfactory spread of points across the curve in Figure 
7 were selected for each construct.  The anti-viral activity profile of each interferon derivative in 
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Figure 8 shows that for four of the constructs (2, 4, 5, 6; figure 1) the experimental points, as 
expected, were satisfactorily spread over the curves, however, in the case of Met-Phe-IFN (3), the 
points were clustered towards the lower half of the curve, which indirectly points to the fact that 
this construct differs from others in having higher activity.  This feature is also indicated by the 
observation that 3 at 0.0374 pM showed similar inhibitory effect (ca.52%) as Met-IFN (3) at 0.374 
pM (ca. 49.4%).  This trend was present at all concentrations.  With the proviso that points in the 
curve for 3 are not broadly scattered, the comparison of the IC50 values in Table 1 indicates that 
this construct is around 8-fold more active than its comparator 2. 
 The fusion of cytochrome b5 at the amino-terminal of interferon (b5-IFN-chimera, 6, Figure 1) 
was advantageous over fusion at the carboxy- terminal (Met-IFN-b5-chimra, 4, Figure 1), since 
the former had 75% bioactivity, relative to the control, compared to 3% for the latter.  This shows 
that an amino terminal, shielded by the b5 domain in b5-IFN-chimera enhances the biological 
activity of the interferon domain. This trend of enhancing the biological activity by a stable N-
terminal appendage is further shown by the fact that the relative bioactivity of Met-Phe-IFN-b5-
chimera (increased to 33% from 1.3% for its comparator). The only difference between the two 
molecules is the presence after the initiator Met of Phe, which protects the N-terminal against the 
action of a peptidase.  The nearly 8-fold increase in activity for construct 2 versus 3 parallels 11 
fold that of 4 versus 5; the difference in both cases is the replacement of N-terminal Met for Met-













Table 1. Relative bioactivities of recombinant interferon and its derivatives prepared in this study 
and those reported in literature.  Numbers in parenthesis refer to structures in Figure 1.The IC50values 
were determined using the online software “IC50 toolkit (ic50.tk)” http://www.ic50.tk/ and counter checked 
by the GraphPad prism7 ® software. International units were calculated as described in the Experimental 
Section. International units (IU) for the constructs g, h and i were calculated from % bioactivity, relative 

















a.  RoferonA 19 - 2.66×1015 100 
b.  Met-IFN (2) 19 0.313 ± 0.13 2.64×1015 100 
c.  Met-Phe-IFN (3) 19.5 0.04 ± 0.02 2.21×1016 837 
d.  Met-IFN-b5-chimera (4) 30.8 16.69 ± 9.9 0.53×1014 2.0 
e.  Met-Phe-IFN-b5-chimera (5) 31 1.53 ± 0.36 6.983×1014 26.4    
f.  b5-IFN-chimera (6) 30.7 0.507 ± 0.07 1.604×1015 60.75   
g.  PEG-Intron 31 - 9.3×1014 35 
h.  PegaSys 59 - 1.86×1014 7 
i.  rHSA/IFNα2b 86 - 3.72×1013 1.4 
j.  Albuferon beta 87 - 7.2×1013 2.7 




Figure 7. Comparative anti-viral activity of Met-IFN (present work) and RoferonA.  A ten-fold serially 
diluted Met-IFN from 374 to 0.0374 fmol/ml was titrated for antiviral activity. Each point represents the 
average value from three independent experiments.  Error bars represent standard deviation values.  The 
units of RoferonA used for comparison are shown next to the symbols. 
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Figure 8. Anti-viral activity of various interferon d 
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Figure 8. Anti-viral activity of various interferon derivatives.  Ten-fold serially diluted 
derivative from 374 to 0.0374 fmol/ml was titrated for antiviral activity. The graphs were 
plotted between percentage infection (linear scale) and conc. (fmol/ml, Log10 scale of conc.) 
of each interferon derivative, using online software programme “IC50 toolkit (ic50.tk)” 
http://www.ic50.tk/, showing the data points of three sets of readings.  The programme 
draws the line, among three sets of readings to give the best sigmoid curve, showing the 
general trend to calculate the minimum and maximum Y-asymptotes, IC50, and Hill-
coefficient of each interferon derivative along with their standard errors. 
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According to Huang et al. [15] a fusion protein between human serum albumin and interferon α-
2b (rHSA/IFNα2b) has 1.4% relative bioactivity when compared on molar basis to unmodified 
interferon. A second fusion construct of interferon β and albumin was estimated from the IC50 
values to have 10% of the antiviral activity compared to interferon β [17].  Of all the fusion proteins 
reported in the literature PEG-intron (12-kDa polyethylene glycol moiety conjugated to interferon 
α-2b) was the most active having 35% of the activity of interferon α-2b (Table 1).  Our comparison 
of the relative bioactivities of the molecules that we have developed has shown that fusion of 
interferon with cytochrome b5 at its amino terminal, (b5-IFN-chimera, 6, Figure 1), gives the most 
active fusion protein; 75% of the activity of interferon α-2b. It is interesting to note that the 
molecular mass of PEG-intron is very similar to that of b5-IFN-chimera.  Furthermore, a simple 
addition of Met-Phe to the N-terminal of IFN (1a Figure 1) produces the highest specific activity 
antiviral protein with 8 fold enhancement over the native cytokine. 
In Table 1 calculated specific activities are stated in international units per mole (mol) as well per 
mg of the proteins.  The relative potency of the constructs, based on their activities, in decreasing 
order is:  
Met-Phe-IFN > Met-IFN=RoferonA> b5-IFN-chimera> Met-Phe-IFN-b5-chimera> Met-IFN-b5-
chimera   
3. Conclusions 
The N-terminal heterogeneity found in the expression of Met-IFN (1a, Figure1) in E. coli was 
mimicked by the fusion construct Met-IFN-b5-chimera (4 Figure 1) which also gave three 
species. These were the primary translation product (MCDLPQT…), another from which the N-
terminal Met was removed and the third arising from the acetylation of the latter.  It is reasonable 
to assume that these post-translation modifications occur within the bacterial cells when the protein 
is unfolded and is, somehow, the property of the interferon N-terminal sequence.  The removal of 
Met by, methionine aminopeptidase is expected because of the small size of the next residue.  
Acetylation of the newly formed N-terminal of Cys is unexpected and such a modification has not 
been reported previously.  However, once the IFN N-terminus is modified to contain a Phe residue 
following the initiator Met, the heterogeneity is abolished as illustrated by Met-Phe-IFN and Met-
Phe-IFN-b5-chimera (3 and 5 Figure 1).  The latter modification has the further advantage of 
enhancing the antiviral activity by about 8 fold relative to their unmodified counterparts; compare 
the activity data of entry b (Met-IFN) with c (Met-Phe-IFN) and d (Met-IFN-b5-chimera) with 
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e (Met-Phe-IFN-b5-chimera) in Table 1.  We cannot tell whether the enhancement of the activity 
is due to stabilization of the N-terminal of the cytokine, by having a peptidase resistant motif, or 
that the Met-Phe sequence improves receptor binding.  However, that the former may be the case 
is indicated by the comparison of the relative activities of proteins carrying the interferon domain 
either at the N- or C-terminal. Construct 6 containing the b5 appendage at the N-terminal is nearly 
2.2 times more active than IFN with b5 at the C-terminal.  Such a behavior is likely explained by 
b5 protecting the interferon from degradation initiated from its N-terminus.   
4. Materials and Methods 
4.1 Construction of Interferon derivatives 
Interferon derivatives were engineered using two plasmids: pET-met-ifn, which contained the 
human interferon α-2b gene, cloned in the pET-21a expression vector [1] and a pT7-7 derivative, 
harbouring the complete gene for the membrane-bound form of human cytochrome b5 (a gift from 
Mrs Monika Akhtar, Biological Sciences, University of Southampton, UK).  T7-promoter and 
ChimR2 primers (Table S1, supplementary) were used for PCR amplification of the soluble 
domain of cytochrome b5. As illustrated in Figure S1, fusion of interferon and b5 domains were 
achieved by placing a XhoI site in between the two domains thus making it possible to stitch the 
interferon DNA either N- or C-terminal to the cytochrome b5 DNA. This feature added two extra 
residues i.e. Leu Glu, at the junction of the two domains in the protein sequence (see 4-6 Figure 
1). The derivatives containing Phe as the second residue, for example 3 and 5 (Figure 1), were 
constructed using Phe-F1 primer (Table S2, Supplementary).  pTZ-57 R/T vector was used for 
cloning PCR amplified DNA fragments and the pET-21a vector was used for expression in this 
study. The derivatives generated in this study are tabulated in Table S3, while Figures S1 A and B 
(Supplementary) summarize the generalized approach adopted to generate the chimeric interferon 
derivatives.  
4.2 Expression and purification of interferon derivatives  
E. coli BL21 codon plus® harboring the appropriate plasmids were grown and inclusion bodies 
isolated as described previously [1]. It was found that solubilization of inclusion bodies at pH 11 
had a beneficial effect on the proper folding and yield of native IFN as well as Met-Phe-IFN (1a 
and 3 Figure 1 respectively).  Following is illustrative of the refolding procedure used for these 
constructs. 
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Inclusion bodies were suspended in a small volume of solubilization buffer (8 M urea, 50 mM 
Tris-HCl pH 8.0, 50 mM glycine), the mixture sonicated on ice, pH adjusted to pH-11.5 with 
NaOH to give a clear solution and volume made up to 5-7 mg of protein/ml using the solublization 
buffer.  To the latter 4 mM DTT was added and the mixture incubated at 37 °C for 30 minutes to 
allow complete reduction of disulfide bridges, while the pH remained 11.5. 
 25 ml of the solubilized protein above (5 mg of protein /ml) was transferred to the refolding sink 
(250 ml, 100 mM Tris-HCl pH 8.0, 2 mM EDTA, 0.5 mM cysteine, 5 mM cystine, 0.1 mM PMSF) 
at a rate of 2.5 ml per hour; the final protein concentration in the refolding sink at the end of 10 
hours was 0.5 mg/ml and the urea concentration was 0.8 M ±0.2 M.   During the latter operation, 
the reaction was gently stirred and maintained at 40C; after 10 hours all the thiols had been lost but 
the pH remained at 8.0. The refolded sample was dialyzed against 20 mM Tris-HCl pH 8.0, with 
4 buffer changes, each after 6 hours, and then the protein was quantified by measuring absorbance 
at 280 nm.    
4.3 Q-sepharose column purification  
Q-FF pre-filled 1 ml or 5 ml Q-sepharose columns (G.E, Healthcare®) were used depending on 
the amount of protein being purified. All the solutions were passed through the column with the 
help of a peristaltic pump (P1- G.E, Healthcare®). The column (washed with 10 column volumes 
of distilled water) was equilibrated with 5 column volumes of 20 mM Tris-HCl pH 8.0.  Refolded 
protein solution was passed through Whatman filter paper 1 by gravitational flow. This solution 
was loaded on the pre-equilibrated column at the rate of 1 ml/min and the flow through was 
collected in bulk in a flask.  At the completion of protein loading, the column was washed again 
with the same buffer (20 mM Tris–HCl pH 8.0) until the OD at 280 nm of the flow-through was 
zero. Protein was eluted with a step-wise gradient of 0.1 to 1 M NaCl.  5 ml of each concentration 
was passed through the column. The protein profile in the collected fractions was monitored by 
SDS-PAGE and the fractions containing the desired protein combined, dialyzed against 0.1% TFA, 
in case of IFN and Met-Phe-IFN or 5 mM Tris-HCl pH 8.0, in case of all chimeras.  The dialyzed 
protein was lyophilized and stored at -20˚C.  The proteins were analyzed by HPLC and mass 
spectrometry. The yield of purified product varied amongst different constructs, ranging from 30 
to 60 percent of the starting inclusion bodies. For the identification of properly refolded proteins, 
tryptic digestion of various interferon constructs was performed as described in [1] and MALDI 
mass spectrometric analysis of fragment containing correct disulphide bridges was performed in 
linear positive mode as described previously [19]. 
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4.4 Bioassays for anti-viral activity of IFN and its derivatives 
In order to measure interferon activity, we measured inhibition of VSV-G pseudotyped HIV-1 
derived vector particles encoding GFP. The particles were generated in HEK-293T cells (described 
in Supplementary Materials) , using a three plasmid system comprising pMDG (encoding VSV-G 
envelope), p8.91 (encoding HIV-1 Gag-pol, Tat and Rev) and pCSGW (HIV-1 genome plasmid 
encoding GFP) [18].  THP-1 cells were infected with the pseudotyped particles in the presence or 
absence of the drug and infected cells measured by flow cytometry for GFP expression 72 hours 
later as detailed below.  
THP-1 cells were grown to 70-80% confluence in RPMI -1640 medium containing 10% FBS. For 
each of the test sample a 12 well plate was used and the respective interferon sample (dissolved in 
solubilizing buffer comprising: NaCl, 7.2 mg/ml; Tween 20, 0.2 mg/ml; ammonium acetate 
0.77mg/ml) was ten-fold serially diluted with DMEM, starting from 374 to 0.0374 fmol/ml (1000 
U/ml to 0.1 U/ml in case of RoferonA), in 5 consecutive wells and one well left untreated with 
medium only. The aforementioned concentrations were used making the assumption that the 
specific activities of the test compounds on per mole basis will be similar to that of RoferonA 
(1.4×108 Units/mg or 2.66×1015 IU/mol) and the duplicate dilutions were made in next 6 wells. 
In each well 105 cells were seeded and incubated overnight at 37 °C with 5% CO2 to provide ample 
time for the induction of antiviral state; the volume at this stage was 1000-900 µl.  Next day 0.1 
ml of the supernatant, containing VSV-G pseudotyped HIV-1 vector with a multiplicity of 
infection (MOI) of 0.3 (multiplicity of infection: ratio of infectious agent to infection target: in this 
case the conditions that infected 33% of the target cells), was added to each well along with 1µl of 
10 mg/ml polybrene solution (final conc. 10µg/ml). Culture was incubated and cells harvested 72 
hours post infection by centrifugation at 1200 x g for 5 minutes.  The cells were fixed with para-
formaldehye by suspending the pellet in 4% para-formaldehyde in PBS. The number of GFP 
positive cells per 10000 counted cells was determined by FACS-analysis.  The decrease in the 
number of GFP positive cells on drug treatment was taken as measure of the antiviral activity of 
interferon and its derivatives.  
The activity units of interferon derivatives were determined by comparison with the activity of a 
standard interferon (RoferonA/interferon α-2b), determined in parallel, as shown in Figures 6 (also 
see Figure S5, supplementary material). The IC50 of a test derivative was taken to be equal to the 
number of units of RoferonA which produced 50% inhibition. For example, Figure 6 shows that 
the inhibition caused by 0.0071 ng (0.374 fmol) of Met-IFN, prepared in the present study, was 
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the same as 1 unit of RoferonA. Therefore, 0.374 fmol of Met-IFN was equal to 1 unit of interferon 
(giving a specific activity, 1.4×108 IU/mg and 2.66×1015 IU/mol) and its IC50 equal to 
0.374fmol/ml (that is 0.374 pM).  Similar equivalence was used to calculate the activity, in Units, 
of other derivatives and their IC50values obtained using an online web-resource “IC50 Tool Kit” 
and the “GraphPad Prism7®” software (Fig.7 and Table 1). 
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